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Background
Head and neck cancer (HNC) is the 8th most common
malignancy worldwide. Despite advances in therapeutic
options over the last few decades, treatment toxicities
and overall clinical outcomes have remained disappoint-
ing, underscoring a need to develop novel therapeutic
approaches, particularly those that enhance tumor cell
death, while minimizing damage to the surrounding nor-
mal tissues.
Materials and methods
An RNA interference (RNAi)-based high-throughput
screen (HTS) was performed for the large-scale identifica-
tion of novel genes that will selectively sensitize HNC cells
to ionizing radiation. The Dharmacon Protein Kinase and
Druggable Genome siRNA Libraries were screened using
FaDu cells (human hypopharyngeal squamous cell cancer).
Radiosensitizing targets were subjected to in vitro and in
vivo characterizations.
Results
Sixty-seven target sequences with potential radiosensitiz-
ing effects were identified. Targets reducing the surviving
fraction by >50% at 2 Gy relative to their un-irradiated
counterparts were selected for further evaluation. A key
regulator of heme biosynthesis, uroporphyrinogen decar-
boxylase (UROD), was thereby identified as a novel
tumor-selective radiosensitizing target, demonstrating
both in vitro and in vivo efficacy. Radiosensitization
appeared to be mediated via enhancement of tumor
oxidative stress from perturbation of iron homeostasis and
increased free radical production. UROD was significantly
over-expressed in HNC patient biopsies, wherein lower
pre-radiation mRNA levels correlated with improved sur-
vival, suggesting UROD could potentially predict radiation
response. UROD down-regulation also radiosensitized sev-
eral different human cancer models, while sparing normal
cells.
Conclusions
An RNAi-based radiosensitizer HTS has revealed UROD
as a potent tumor-selective sensitizer for radiation, with
potential relevance to many human malignancies.
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